New pill aims to ease schizophrenia episodes

NCT ID NCT07467993

Recruiting now Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tests an experimental oral drug called GXV813 in 142 hospitalized adults with schizophrenia. The goal is to see if it safely reduces symptoms like hallucinations and withdrawal during an acute episode. Participants are randomly assigned to receive GXV813 or a placebo, and neither they nor their doctors know which they get.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GXV813 (an oral drug)
What this could lead to: If it works, this could point toward a new treatment option for acute schizophrenia episodes, helping reduce severe symptoms.
What could go wrong: This is an early Phase 2a trial with only 142 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Arch Clinical Trials LLC
RECRUITING

St Louis, Missouri, 63141, United States
CNRI Los Angeles LLC
RECRUITING

Pico Rivera, California, 90660, United States
CenExel iResearch
RECRUITING

Decatur, Georgia, 30030, United States
Novartis Investigative Site
RECRUITING

Sofia, BGR, 1431, Bulgaria
Novartis Investigative Site
RECRUITING

Haskovo, 6300, Bulgaria
Novartis Investigative Site
RECRUITING

Kazanlak, 6100, Bulgaria
Novartis Investigative Site
RECRUITING

Lovech, 5500, Bulgaria
Novartis Investigative Site
RECRUITING

Plovdiv, 4002, Bulgaria
Novartis Investigative Site
RECRUITING

Sliven, 8800, Bulgaria
Novartis Investigative Site
RECRUITING

Sofia, 1377, Bulgaria
Novartis Investigative Site
RECRUITING

Veliko Tarnovo, 5000, Bulgaria
Novartis Investigative Site
RECRUITING

Vratsa, 3000, Bulgaria
Pillar Clinical Research LLC
RECRUITING

Bentonville, Arkansas, 72712, United States
Pillar Clinical Research LLC
RECRUITING

Chicago, Illinois, 60641, United States
Segal Institute for Clinical Research
RECRUITING

Miami, Florida, 33016, United States
Uptown Research Institute LLC
RECRUITING

Chicago, Illinois, 60640, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.